Patents by Inventor Annabell Francis Leske

Annabell Francis Leske has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Predictive biomarkers
    Patent number: 10564162
    Abstract: The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 18, 2020
    Assignee: BIONOMICS LIMITED
    Inventors: Gabriel Kremmidiotis, Annabell Francis Leske
  • Predictive baseline biomarkers for use of vascular disrupting agents
    Patent number: 10520508
    Abstract: The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: December 31, 2019
    Assignee: Bionomics Limited
    Inventors: Gabriel Kremmidiotis, Annabell Francis Leske
  • PREDICTIVE BASELINE BIOMARKERS FOR USE OF VASCULAR DISRUPTING AGENTS
    Publication number: 20180196056
    Abstract: The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 12, 2018
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Annabell Francis LESKE
  • PREDICTIVE BIOMARKERS
    Publication number: 20180196048
    Abstract: The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 12, 2018
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Annabell Francis LESKE
  • Methods of identifying agents that inhibit angiogenesis
    Patent number: 8309351
    Abstract: The presently disclosed subject matter relates to the identification of markers of endothelial cells which are in a quiescent or activated state, and more specifically to beta tubulin isotypes as markers which are differentially expressed between endothelial cells in these states. The beta tubulin isotypes can be used for the identification of candidate agents which selectively bind quiescent or activated endothelial cells, and to identify candidate agents which inhibit or promote angiogenesis and/or vascular function.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: November 13, 2012
    Assignee: Bionomics Limited
    Inventors: Gabriel Kremmidiotis, Annabell Francis Leske
  • MARKERS OF ENDOTHELIAL CELLS AND USES THEREOF
    Publication number: 20100285497
    Abstract: Use of a beta tubulin isotype that is differentially expressed between activated endothelial cells and quiescent endothelial cells for identifying an agent which inhibits or promotes angiogenesis and/or vascular function.
    Type: Application
    Filed: October 2, 2008
    Publication date: November 11, 2010
    Inventors: Gabriel Kremmidiotis, Annabell Francis Leske